Table 1.
– Comparative clinico-pathologic characteristics pre-HIFU, pre-sRARP and post-sRARP (n = 45)
| Variables | Pre-HIFU | Pre-sRARP | Final sRARP pathology |
|---|---|---|---|
| Age, years (IQR) | 62 (IQR 60–66) | 63.0 yrs. (IQR 61–66) | – |
| PSA, median (IQR) | 7.3 (5.5–8.9) | 6 (3.9–10.0) | – |
| Gleason score, n (%): | |||
| 3 + 3 | 9 (20.0) | 3 (6.7) | 0 (0) |
| 3 + 4 | 29 (64.4) | 22 (48.9) | 22 (48.9) |
| 4 + 3 (or 3 + 4 with tertiary grade 5) | 5 (11.1) | 15 (33.3) | 18 (40.0) |
| 4 + 4 (or 4 + 3 with tertiary grade 5) | 2 (4.4) | 2 (4.4) | 1 (2.2) |
| 4 + 5 | – | 3 (6.7) | 4 (8.9) |
| T-stage*, n (%): | |||
| T2 | 43 (95.6) | 40 (88.9) | 16 (35.6) |
| T3a | 2 (4.4) | 4 (8.9) | 21 (46.7) |
| T3b | – | 1 (2.2) | 8 (17.8) |
| Max cancer core length in mm, median (IQR) | 7 (5–10) | 6 (3–8) | n/a |
| Number of cores taken, median (IQR) | 36 (14–58) | 13 (8–24) | n/a |
| Percentage of positive cores, median (IQR) | 17 (11–30) | 30 (14–40) | n/a |